Adverse effects other than ototoxicity (≥ grade 3 according to NCICTCAEv3 criteria) with intravenous platinum · children with cancer treated with platinum‐based therapy
1 finding from 1 review
Quality of life · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Ototoxicity according to NCI CTC v2 criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Objective and subjective audiometric evaluations were performed, no further information provided · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in ototoxicity according to NCICTCv2 criteria with intravenous platinum… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Ototoxicity according to modified Brock criteria with intravenous platinum (combined asymptomatic and symptomatic disease) Audiograms were performed, but no further information provided · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in ototoxicity according to modified Brock criteria with intravenous… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Survival · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Survival (overall and event‐free) ‐ not reported · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tumour response with intra‐arterial platinum (good and partial remission) · children with cancer treated with platinum‐based therapy
Amifostine showed no clear difference in tumour response with intra‐arterial platinum (good and partial… compared with no otoprotective intervention (low certainty).
1 finding from 1 review
Renal toxicity / vomiting/ cardiotoxicity (all grade 3 or higher according to NCI CTCv2 criteria) with intra‐arterial platinum · children with cancer treated with platinum‐based therapy
1 finding from 1 review
Quality of life · children with cancer treated with platinum‐based therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
Leaving the study early · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in dropouts compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Response (≥ 50% improvement in BDI‐II score) · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in response (≥ 50% improvement in BDI‐II score) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI/SNRI) with mirtazapine… showed no clear difference in remission (BDI‐II total score ≤ 9) compared with augmentation of current antidepressant (SSRI/SNRI) therapy with… (high certainty).
1 finding from 1 review
Quality of life (EQ‐5D‐5L) ‐ 12 weeks · treatment‐resistant depression in adults
1 finding from 1 review
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
Dropouts ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher dropouts ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Response (≥ 50% reduction in MADRS or HAM‐D score) ‐ Any dose · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… probably leads to higher response (≥ 50% reduction in MADRS/HAM‐D score) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review
Remission · treatment‐resistant depression in adults
Augmentation of current antidepressant (SSRI) with ziprasidone (40… showed no clear difference in remission (clinician‐rated) ‐ Any dose compared with augmentation of current antidepressant (SSRI) with placebo or… (moderate certainty).
1 finding from 1 review